GlassScriptPhysician profile
Judith Baker
NPI 1639553639
$1,472.46
in general payments reported to CMS, 2019-2025
27 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $393 · 2022: $286 · 2023: $289 · 2024: $203 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $438.85 | 2021-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $91.88 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $80.84 | 2021-2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $69.70 | 2022-2024 | Veozah |
| Abbvie INC. | $63.04 | 2021 | |
| Abbott Laboratories | $60.56 | 2023 | Freestyle Libre |
| Phathom Pharmaceuticals, INC. | $54.43 | 2024-2025 | Voquezna |
| Pfizer INC. | $53.46 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.43 | 2023-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $47.23 | 2021 | |
| Lilly USA, LLC | $46.69 | 2024 | Mounjaro, Zepbound |
| Sumitomo Pharma America, INC. | $42.06 | 2024-2025 | Gemtesa |
| Esperion Therapeutics, INC. | $41.02 | 2021 | |
| Dexcom, INC. | $39.44 | 2024-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $37.89 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $35.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.84 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.79 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.01 | 2021 | |
| Tolmar, INC. | $23.00 | 2025 | Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $21.66 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.26 | 2025 | Bevespi Aerosphere |
| Eisai INC. | $17.76 | 2021 | |
| Exact Sciences Corporation | $15.84 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $14.79 | 2021 | |
| Acerus Pharmaceuticals Corporation | $14.03 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.16 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.